| Name | Title | Contact Details |
|---|
French Family-owned URGO Group is an international leading company and world expert in advanced wound care and selfcare. With its two divisions Urgo Medical and Urgo Consumer Healthcare, URGO Group is engaged on day to day basis with patients, healthcare professionals and the general public. The Group develops innovative wound dressings that have proven their medical superiority through clinical studies, to address an increased need worldwide for the care of chronic wounds. It gives access to responsible healthcare solutions in the areas of first aid, nutritional supplements, sexual well-being, cold and allergies. 3 300 collaborators participate in these missions in 22 countries, among which 10 industrial sites serve the needs of our clients.
Universal Health Services, Inc. (NYSE: UHS) is a Fortune 500 company based in King of Prussia, Pennsylvania. UHS owns and operates acute care hospitals, behavioral health centers, and ambulatory surgery centers in 37 states, Puerto Rico and the U.S. Virgin Islands. Universal Health Services, Inc. (UHS) is one of the largest hospital management companies in the United States. Through its subsidiaries, UHS operates 226 acute care hospitals, behavioral health facilities and ambulatory surgery centers. The company employs more than 60,000 people.
NuvoAir is a virtual first specialty care provider that empowers and engages people living with complex heart and lung conditions like COPD, Congestive Heart Failure (CHF), and Asthma around the world.
Taiho Oncology, Inc. strives to make a positive contribution to society and the environment. We support our local communities through charitable endeavors, and we work proactively to protect the environment by minimizing the environmental impact in every aspect of our work-from research and development to production, distribution, marketing, and disposal. Furthermore, as a member of Otsuka Holdings, we are part of a group of companies that pursues initiatives that are shaped by mutual respect and open communication with all stakeholders, including customers and business partners in the countries and regions where we do business.
Since 1975, PSEF has provided more than $5. 3 million to plastic surgery researchers for the development of innovative procedures and treatments that benefit reconstructive and cosmetic patients today. Funding for plastic surgery research is made